Receptor News and Research

RSS

Engineered albumin could lead to needle-free, long-lasting protein medicines

Protein-based medicines have transformed the treatment of many diseases, but they often come with a limitation: they must be injected, sometimes repeatedly, because they are rapidly cleared from the bloodstream.

28 Oct 2026

Most adults with obesity did not meet food noise criteria in US survey

Researchers analyzed responses from 3,646 US adults not currently taking GLP-1 medications to assess persistent, unwanted food-related thoughts using a five-item questionnaire. They found that approximately 4% to 9.5% met questionnaire-based criteria for food noise, with higher scores among younger adults, women, and people in higher BMI categories, while cautioning that no clinically validated threshold exists.

27 Oct 2026

Plasma proteins offer clues to biological aging and mortality risk

A new study published in Geromedicine has identified 17 plasma proteins associated with all-cause mortality in older adults and found that several of these proteins also track with measures of biological aging across multiple organ systems.

27 Oct 2026

High-scoring endocrinologists are more likely to prescribe key diabetes drugs

Endocrinologists who scored highest on the American Board of Internal Medicine's Longitudinal Knowledge Assessment (LKA®) were more likely to prescribe a key diabetes drug class following a treatment guidelines update compared to doctors with lower scores.

27 Oct 2026

Study establishes new perioperative standard in prostate cancer

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide - a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.

27 Oct 2026

New alpha-emitting radiopharmaceutical therapy achieves strong responses in advanced prostate cancer

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a phase 1 trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.

26 Oct 2026

Millions get GLP-1 drugs through channels insurance records may miss

Researchers analyzed reports from 9,150 US adults and found that current or previous GLP-1/GIP use rose from 8.2% to 12% between March 2024 and October 2025, largely driven by weight-loss indications. They also estimated that approximately one-third of users obtained treatment through nontraditional channels that standard insurance claims may fail to capture.

26 Oct 2026

Semaglutide changes gut bacteria in rats beyond what eating less explains

Researchers compared semaglutide-treated male and female rats with pair-fed animals receiving the same amount and type of food to distinguish drug-associated microbiome changes from those linked to reduced eating. Semaglutide altered bacterial richness and community composition, with some changes absent from the pair-fed groups and uncertain consequences for health.

26 Oct 2026

Smart probe makes aggressive breast cancer cells glow during surgery

Surgical removal of a tumor remains the primary defense against most solid cancers. However, for surgeons in the operating room, differentiating between the outer edges of a tumor and healthy tissue is a challenge.

26 Oct 2026

Researchers discover how faulty matrix structure leads to cell death in newly formed bone

Bone cells called osteocytes help maintain skeletal strength, but how newly formed osteocytes survive remains unclear.

26 Oct 2026

Clues to prostate cancer risk in blood samples taken 15 years earlier

Recent study links blood proteins to aggressive prostate cancer, identifying potential biomarkers for early risk prediction and insights into immune activity.

26 Oct 2026

Taking a GLP-1 drug? Here's what the safety evidence really shows

A review on GLP-1 receptor agonists highlights risks like pancreatitis and thyroid cancer, emphasizing individual patient risk over general safety concerns.

26 Oct 2026

Abiraterone triplet therapy improves long-term survival in metastatic prostate cancer

Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification.

24 Oct 2026

Study reveals how cancer cells survive chemotherapy in a zombie-like state

Scientists at Trinity College Dublin have made an important breakthrough in understanding how cancer cells can evade the cell-killing effects of chemotherapy and enter a "zombie-like state", called premature senescence, that can attract the wound healing properties of the immune system.

23 Oct 2026

Modulating GPCR signaling could help delay multiple age-related diseases

Researchers have outlined a bold plan for slowing aging by targeting one of the body's most important cellular communication systems.

22 Oct 2026

AGA/AASLD joint guideline evaluates newer medications for primary biliary cholangitis

For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for the Study of Liver Diseases (AASLD) evaluates newer medications for primary biliary cholangitis (PBC), the most common cholestatic disease in adults.

22 Oct 2026

Semaglutide and teduglutide reduce immune-driven gut injury in mice

Researchers found that gut-derived GLP-1 and GLP-2 signaling helped protect mice against T cell-induced intestinal injury, with GLP-1R primarily regulating inflammation and GLP-2R supporting intestinal repair. Semaglutide and teduglutide, administered separately or together, reduced acute intestinal damage in mice lacking intestinal proglucagon, suggesting potential avenues for investigating treatments for immune-mediated gut injury.

21 Oct 2026

Altered fatty acid metabolism drives glioblastoma growth and treatment resistance

Glioma is the most common primary malignant brain tumor in adults, and glioblastoma (GBM), particularly IDH (Isocitrate dehydrogenase)-wildtype disease, has the poorest prognosis.

21 Oct 2026

Scientists discover natural cellular defense mechanism against ALS progression

ALS is a disease where, in most cases, a protein forms aggregates in neurons, which leads to the rapid loss of motor control and death.

20 Oct 2026

GLP-1 drugs may protect kidney health in people with bipolar disorder

Mayo Clinic researchers found that GLP-1 receptor agonists, medications widely used for diabetes and weight management, were associated with a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease.

20 Oct 2026